Cel-Sci Corporation (CVM)
CVM trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.75
-4.37% on the day
Market cap
$30.8M
Nano cap
Revenue
No annual revenue filed since the period ending 2014-09-30
Net income
No annual revenue filed since the period ending 2014-09-30
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CVM on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 1997 |
| SEC CIK | 0000725363 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | CO |
Financials
No annual revenue filed since the period ending 2014-09-30.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2026-06-15 |
| Latest annual report FORM 10-K | 10-K | 2025-12-29 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-14 |
| Latest current report FORM 8-K | 8-K | 2026-08-17 |
| Latest proxy | DEF 14A | 2026-07-02 |
Source: SEC EDGAR submissions feed, 1,007 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELUT | Elutia Inc. | $0.7732 | -1.75% | $34.2M |
| ALGS | Aligos Therapeutics Inc. | $5.51 | -0.36% | $34.4M |
| MGX | Metagenomi Therapeutics Inc. | $0.9173 | -10.07% | $34.7M |
| GNTA | Genenta Science S.p.A. | $0.7220 | -4.99% | $34.8M |
| EVAX | Evaxion A/S American Depositary Share | $2.76 | -8.00% | $24.9M |
| TIL | Instil Bio Inc. | $6.18 | -6.08% | $41.9M |
| BSEM | BioStem Technologies Inc. | $2.25 | -7.79% | $42.0M |
| EXOZ | eXoZymes Inc. | $4.59 | -9.11% | $42.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier